IVF

Illume Fertility Partners with TMRW Life Sciences to Provide Cutting Edge Technology for the Safe Management and Storage of Frozen Eggs and Embryos for Patients

Retrieved on: 
Tuesday, January 23, 2024
Patient, Fertility, Partner, IVF, Failure, Embryology, Risk, TMRW, Safety, Laboratory, FDA, Parent

NORWALK, Conn., Jan. 23, 2024 /PRNewswire-PRWeb/ -- Illume Fertility, a leading modern fertility practice whose exceptional quality of care helps hopeful parents grow their families, and TMRW Life Sciences, a fertility technology company, have partnered to provide Illume's patients with the world's first and only FDA-approved, automated platform for accurate management and storage of frozen eggs and embryos.

Key Points: 
  • "Tracking our patients' precious eggs and embryos is now completely digitized and seamless."
  • Illume Fertility is the only fertility center in Connecticut that has a TMRW cryo robot, and was one of the first fertility clinics in the United States to incorporate TMRW Life Sciences' automated platform into their lab.
  • The storage of eggs and embryos has always been a manual process in IVF laboratories, but with TMRW's automated platform, potential points of failure have been reduced by 93%.
  • Illume Fertility's clinicians have now modernized their specimen management and storage practices, utilizing TMRW's digital tools onsite in addition to transferring patient specimens offsite to and from TMRW Cryobanks.

CCRM FERTILITY ANNOUNCES CHELSEY LEISINGER AS NEW VP OF NETWORK LAB COMPLIANCE

Retrieved on: 
Monday, January 22, 2024
Patient, Fertility, Research, Iowa State University, IVF, Science, Embryology, University School, Bachelor of Science, Laboratory, Certification, Doctor of Philosophy, Veterinary medicine, University college, Medical device

LONE TREE, Colo., Jan. 22, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today the appointment of Chelsey Leisinger, MS, PhD, HCLD/CC as VP of Network Lab Compliance.

Key Points: 
  • Dr. Leisinger joins CCRM's leading team of fertility specialists, focusing on laboratory compliance
    LONE TREE, Colo., Jan. 22, 2024 /PRNewswire/ -- CCRM Fertility, a leading pioneer in the fertility treatment, research, and science industry, announced today the appointment of Chelsey Leisinger, MS, PhD, HCLD/CC as VP of Network Lab Compliance.
  • As the newly appointed Vice President of Network Lab Compliance for CCRM, Dr. Leisinger, a renowned fertility specialist, will play a pivotal role in supervising select laboratory locations.
  • Her primary focus will be on ensuring laboratory compliance and risk mitigation, thereby elevating the fertility experience for both CCRM laboratory technologists and patients.
  • "I am thrilled to join the CCRM Fertility expert team to help further the mission of providing top-notch fertility care," said Dr. Leisinger.

Florida Reproductive Specialists by IVF FLORIDA Introduces World-Class Fertility Care to North Florida

Retrieved on: 
Wednesday, January 17, 2024
Patient, Fertility, Gynaecology, IVF, Partnership, Cancer, Fertilisation, Suite, Fertility preservation, Birth control

Florida Reproductive Specialists is dedicated to delivering state-of-the-art technology, inclusive fertility care, and compassionate medical guidance.

Key Points: 
  • Florida Reproductive Specialists is dedicated to delivering state-of-the-art technology, inclusive fertility care, and compassionate medical guidance.
  • Florida Reproductive Specialists is a partner with IVF FLORIDA Reproductive Associates , a reputable provider of fertility treatments in South Florida since 1986.
  • With multiple locations throughout Florida, both Florida Reproductive Specialists and IVF FLORIDA Reproductive Associates deliver comprehensive and empathetic care to individuals and couples pursuing family-building solutions.
  • Florida Reproductive Specialists and IVF FLORIDA are proud partner practices of US Fertility , the largest physician-owned and physician-led partnership of top-tier fertility practices nationally.

Ivy Fertility and SMP Pharmacy Solutions Launch Co-Branded Partnership

Retrieved on: 
Tuesday, January 16, 2024
Women, Baby, Maternity, Genetics, Biotechnology, Family, Health, Consumer, Pharmaceutical, General Health, IVF, Organization, Partnership, Pharmacy, Patient, Physician, SMP, Birth control

Ivy Fertility, a global destination for family-building services, is partnering with fertility specialty pharmacy SMP Pharmacy Solutions to elevate the patient experience across Ivy’s 13 fertility centers through an innovative co-branding initiative.

Key Points: 
  • Ivy Fertility, a global destination for family-building services, is partnering with fertility specialty pharmacy SMP Pharmacy Solutions to elevate the patient experience across Ivy’s 13 fertility centers through an innovative co-branding initiative.
  • Ivy Fertility is known for its high-touch care and compassionate physicians, but the majority of any IVF process actually takes place outside of the fertility clinic.
  • “Creating a partnership with SMP enhances the end-to-end patient experience and uplevels the expectations of what’s possible,” said Ivy Fertility Chief Growth Officer Constance Rapson.
  • By working together to extend support beyond the walls of the clinic, Ivy Fertility and SMP Pharmacy Solutions aim to make every aspect of the fertility journey as comforting as possible.

Cell Cryopreservation Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Biotechnology, Health, Medical Devices, Conditional sentence, Cryopreservation, Regenerative medicine, Cell, Research, Infertility, B cell, IVF, Risk, Tissue engineering, COVID-19, Sigma-Aldrich, Biobank, Stem cell, Prevalence

The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The increased demand for cost-effective cryopreservation medium has stemmed from increased research & development (R&D) activities to create advanced medicines.
  • For example, Merck KGaA's Sigma Aldrich brand provides frozen media solutions for stem cell applications while ensuring optimal recovery and cell survival, thus, propelling the cryopreservation market growth.
  • Additionally, developments in freezing media formulation and cryopreservation techniques, as well as leveraging cryopreservation freezing media applications in fields such as tissue engineering, cellular treatment, and stem cell research, have driven the market at a substantial rate.

New CCRM Fertility Location Opens in Jersey City, NJ

Retrieved on: 
Thursday, January 11, 2024
Patient, Fertility, MD, Infertility, IVF, University Medical Center, Johns Hopkins, University, Johns Hopkins Hospital, IRMS, IUI, York Street, NYU Langone Health, Birth control

JERSEY CITY, N.J., Jan. 11, 2024 /PRNewswire/ -- CCRM Fertility is opening a new clinic location in Jersey City to provide patients with greater access to its full array of fertility treatments and services in New Jersey. This now totals eight locations in New Jersey, which became part of the CCRM network when IRMS was acquired in June 2022. All existing IRMS locations will be rebranded to CCRM Fertility by 2025.

Key Points: 
  • JERSEY CITY, N.J., Jan. 11, 2024 /PRNewswire/ -- CCRM Fertility is opening a new clinic location in Jersey City to provide patients with greater access to its full array of fertility treatments and services in New Jersey.
  • The new, state-of-the-art Jersey City location will be led by Dr. Stephanie Marshall Thompson, MD and Dr. Serena H. Chen, MD .
  • "We are thrilled to open another location in the Tri-State Area," said CEO CCRM Fertility Bob LaGalia.
  • "I'm excited to expand CCRM further and bring top-tier fertility care to patients in Jersey City," said Dr. Thompson.

AIVF Recognized Among Top 50 Most Promising Digital Health Startups by CB Insights

Retrieved on: 
Wednesday, January 10, 2024
Digital, IVF, Digital health, Patient, Pregnancy, CB Insights, Ecosystem, Retail

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- AIVF, a leader in AI solutions for in vitro fertilization (IVF), has been named one of the top 50 most promising digital health startups globally by CB Insights. CB Insights announced the prestigious recognition as part of its fifth annual Digital Health 50, a distinguished list celebrating the companies transforming the healthcare landscape.

Key Points: 
  • NEW YORK, Jan. 10, 2024 /PRNewswire/ -- AIVF , a leader in AI solutions for in vitro fertilization (IVF), has been named one of the top 50 most promising digital health startups globally by CB Insights .
  • CB Insights announced the prestigious recognition as part of its fifth annual Digital Health 50 , a distinguished list celebrating the companies transforming the healthcare landscape.
  • "We are honored to be identified by CB Insights to be among the top 50 digital health startups globally," said Daniella Gilboa, CEO of AIVF.
  • AIVF's inclusion in the Digital Health 50 is a testament to the company's exceptional performance and commitment to advancing the field of digital health.

Kindbody Opens in Walnut Creek; Marks Four Years of Serving Patients and Employers with Transformative Reproductive Healthcare in the San Francisco Bay Area

Retrieved on: 
Tuesday, January 9, 2024
Silicon, Northwestern University, Patient, UCSF, Fertility, Infertility, IVF, REI, University, Gynaecology, Biomedical engineering, Obstetrics and gynaecology, San Francisco General Hospital, Hospital, Obstetrics, Parent, Georgia Tech, El Camino Real, Nursing

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, today announced the opening of Kindbody East Bay, its state-of-the-art clinic and IVF lab at 1700 N. Main Street in Walnut Creek, CA. The announcement comes at a time of extraordinary growth for the company which owns and operates 34 clinics nationwide, including a state-of-the-art fertility clinic and IVF lab in downtown San Francisco at 88 Sutter Street and a Silicon Valley location at 4756 El Camino Real in Los Altos. Kindbody East Bay was built to meet the growing demand for comprehensive fertility and family-building benefits that cover the full spectrum of reproductive care by Bay Area employers. The clinic is led by Dr. Geraldine Ekpo, a fertility specialist who is board-certified in both reproductive endocrinology and obstetrics and gynecology.

Key Points: 
  • Kindbody East Bay was built to meet the growing demand for comprehensive fertility and family-building benefits that cover the full spectrum of reproductive care by Bay Area employers.
  • The opening of Kindbody East Bay follows four years of serving employers and patients throughout the San Francisco Bay Area.
  • Dr. Ekpo is currently accepting new patients at the East Bay location and will continue to serve patients in San Francisco.
  • Employers who wish to learn more about how Kindbody delivers the best patient experience and outcomes while reducing healthcare costs can contact [email protected] .

Paterna Biosciences Announces Renowned Reproductive Biology Scientist Dr. Kyle Orwig as Co-Founder

Retrieved on: 
Monday, January 8, 2024
Biotechnology, General Health, Health, Other Health, Transplant, Paterna, Research, IVF, Male, Infertility, Reproduction, Fertility, University, UPMC Magee-Womens Hospital, Knowledge, Spermatogenesis, Obstetrics, Gynaecology, Birth control

Paterna Biosciences , a ground-breaking innovator in biotechnology and reproductive health, is pleased to announce Dr. Kyle Orwig has joined the company as a co-founder.

Key Points: 
  • Paterna Biosciences , a ground-breaking innovator in biotechnology and reproductive health, is pleased to announce Dr. Kyle Orwig has joined the company as a co-founder.
  • In addition to his co-founder role, Orwig is currently professor of obstetrics, gynecology and reproductive sciences at the University of Pittsburgh.
  • Paterna Biosciences CEO Ed Rowland said, "Paterna Biosciences is thrilled to welcome Kyle Orwig to our team.
  • "I am honored and excited to join the exceptional team at Paterna Biosciences, many of them longtime colleagues," said Orwig.

ReproTech Launches Cryo-Logix, a New Entity Designed to Provide In Vitro Fertilization Clinics with a Holistic and Seamless End-to-End Cryostorage Solution

Retrieved on: 
Monday, January 8, 2024
General Health, Health Technology, Health, IVF, Wildfire, EMR, Patient, Food and Drug Administration, Communication, Nursing

ReproTech LLC (“ReproTech” or the “Company”), the industry leader in human reproductive tissue cryogenic storage, today announced the launch of Cryo-Logix , a new entity specializing in providing In vitro fertilization (“IVF”) clinics with a seamless end-to-end cryostorage solution.

Key Points: 
  • ReproTech LLC (“ReproTech” or the “Company”), the industry leader in human reproductive tissue cryogenic storage, today announced the launch of Cryo-Logix , a new entity specializing in providing In vitro fertilization (“IVF”) clinics with a seamless end-to-end cryostorage solution.
  • Cryo-Logix will operate as a separate entity within ReproTech and will focus on enabling IVF clinics to provide better care to their patients from the time of consent until the time of disposition.
  • Brad Senstra, Chief Executive Officer of ReproTech, said, “IVF clinics have been searching for a best-in-class end-to-end cryostorage solution that reduces the risks of storing human tissue on-site at fertility clinics.
  • ReproTech also has multi-layer monitoring and redundant proprietary systems in place to protect precious reproductive tissue specimens.